Heavier FTC Scrutiny Puts Pressure On Consumer Health Product Claims
This article was originally published in The Tan Sheet
Executive Summary
Attorneys say marketers should make structure/function claims with knowledge that no claims are safe from FTC scrutiny. During the Food & Drug Law Institute annual meeting, stakeholders commented on how FTC’s stance on Bayer Health Care’s Philips Colon Health will impact other claims.
You may also be interested in...
FTC Requests Drug Claim Support For Bayer Probiotic Supplement
On behalf of the FTC, DoJ alleges Bayer violated a 2007 settlement to substantiate supplement claims and asks a court to require the firm to provide two RCTs for dietary supplement claims for Phillips’ Colon Health. Trade groups rally behind the firm, arguing the requirement is unfair and illegal.
Target Corp.'s ‘Clean’ Marketing Challenged In Consumer Class Action
The mega-retailer is defending a proposed class action in Minnesota federal court over its ‘Target Clean’ marketing and label, which it has awarded "independently" to around 4,000 products in its stores. Consumer plaintiffs allege some offerings contain ingredients on the program's “formulated without” list, as well as other hazardous substances that ought not be in clean products. Pending litigation against Sephora stands to be influential.
FDA Unveils MoCRA Registration Portal: Meet ‘Cosmetics Direct’
FDA introduces Cosmetics Direct for registering manufacturing facilities and listing products, a little more than three months from registration deadlines set by new cosmetics regulations, and provides looks at the forms companies will need to submit. For now at least, the 29 December deadlines stand, notwithstanding stakeholder pressure for extensions or enforcement discretion.